中文
  • 投资者关系
  • 新闻动态
  • 公司新闻
  • 行业新闻
  • 法规动态
  • 联系我们
  • 招贤纳士
  • 招标公告
  • 法规动态

    当前位置: 首页 > 新闻动态 > 法规动态

    Infliximab May Be Better Than Adalimumab For Ulcerative Colitis.

    2013-10-16

    MedPage today reports that research presented at the annual meeting of the American College of Gastroenterology suggests that “for patients with ulcerative colitis considering treatment with anti-tumor necrosis factor (TNF) therapy, infliximab (Remicade) may be a better choice than adalimumab (Humira).” Researchers found, “in a meta-analysis of studies that compared each of these anti-TNF agents with placebo,” that “odds ratios for remission after 8 weeks of induction therapy were 5.26 (95% CI 2.94-9.99) for infliximab and 2.22 (95% CI 1.23-3.98) for adalimumab.” Then, “using Bayesian random-effect indirect comparison meta-analysis, the” investigators “determined that the odds ratio for remission with adalimumab compared with infliximab was 0.42 (95% CI 0.17-0.97).”

    上一篇:没有了

    下一篇:没有了